Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Summary

This pilot clinical trial studied how well desipramine hydrochloride and filgrastim worked for stem cell mobilization in participants with multiple myeloma (MM) undergoing stem cell transplant. Giving colony-stimulating factors, such as filgrastim, and other drugs, such as desipramine hydrochloride, helps stem cells move from the participant's bone marrow to the blood so they can be collected and stored.

Timeline

Start

2013-09

Primary completion

2015-03

Completion

2015-03

Outcome

Outcome not reported

Stopped (Enrollment): “The study was stopped during the interim analysis due to low accrual after the widespread use of plerixafor for multiple myeloma in the United States.”

Drugs

Indications